[HTML][HTML] A'diamond'approach to personalized treatment of angina

R Ferrari, PG Camici, F Crea, N Danchin… - Nature Reviews …, 2018 - nature.com
In clinical guidelines, drugs for symptomatic angina are classified as being first choice (β-
blockers, calcium-channel blockers, short-acting nitrates) or second choice (ivabradine …

Treatment of angina: where are we?

C Balla, R Pavasini, R Ferrari - Cardiology, 2018 - karger.com
Ischaemic heart disease is a major cause of death and disability worldwide, while angina
represents its most common symptom. It is estimated that approximately 9 million patients in …

Angina and its management

RA Kloner, B Chaitman - Journal of cardiovascular …, 2017 - journals.sagepub.com
Angina pectoris is defined as substernal chest pain, pressure, or discomfort that is typically
exacerbated by exertion and/or emotional stress, lasts greater than 30 to 60 seconds, and is …

Anti-anginal drugs–beliefs and evidence: systematic review covering 50 years of medical treatment

R Ferrari, R Pavasini, PG Camici, F Crea… - European heart …, 2019 - academic.oup.com
Chronic stable angina is the most prevalent symptom of ischaemic heart disease and its
management is a priority. Current guidelines recommend pharmacological therapy with …

Pharmacological and emerging therapies in the treatment of chronic angina

SE Husted, EM Ohman - The Lancet, 2015 - thelancet.com
Chronic angina is a common manifestation of ischaemic heart disease. Medical treatments
are the mainstay approach to reduce the occurrence of angina and improve patients' quality …

Angina with “normal” coronary arteries: a changing philosophy

R Bugiardini, CNB Merz - Jama, 2005 - jamanetwork.com
ContextMany women with angina are told that they have no significant heart disease
following demonstration of normal or near-normal coronary arteries and are offered no …

Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis

J Belsey, I Savelieva, A Mugelli… - European Journal of …, 2015 - academic.oup.com
Aims First-line medical management of stable angina generally involves a beta-blocker (BB)
or calcium channel blocker (CCB), with other classes of medication being added if symptom …

[HTML][HTML] Pharmacological treatment of chronic stable angina pectoris

JM Tarkin, JC Kaski - Clinical medicine, 2013 - Elsevier
Chronic stable angina is the most common manifestation of ischaemic heart disease in the
developed world and is associated with impaired quality of life and increased mortality. The …

Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization

R Kones - Vascular Health and Risk Management, 2010 - Taylor & Francis
The objectives in treating angina are relief of pain and prevention of disease progression
through risk reduction. Mechanisms, indications, clinical forms, doses, and side effects of the …

Recent advances in the management of chronic stable angina I: approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities

R Kones - Vascular health and risk management, 2010 - Taylor & Francis
The potential importance of both prevention and personal responsibility in controlling heart
disease, the leading cause of death in the USA and elsewhere, has attracted renewed …